TNXP News and Press, Tonix Pharmaceuticals Holding Corp. From 10/25/22

CHATHAM, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,400,000 shares of Seri...

CHATHAM, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Jessica Morris, Chief Operating Officer of Tonix Pharmaceuticals, will present at the ThinkEquity Conference on Wednesday, Oc...

NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street , a nationally syndicated TV show, announces episode #397 airing on the Fox Business Network, tonight, Monday, October 17, 2022, at 10:30 PM PT. 1). The Sustainable Green Team&#x...

CHATHAM, N.J., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will participate in one-on-one meetings at the 2022 BI...

NEW YORK, Oct. 14, 2022 (GLOBE NEWSWIRE) -- FMW Media’s New To The Street / Newsmax announces its 396th show lineup, which features the following nine (9) Corporate interviews, airing Sunday, October 16, 2022, 10-11 AM ET: 1). The Sustainable Team’s (...

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- FMW Media’s New to The Street announces the broadcasting of its business show broadcasting as a sponsored program on Bloomberg TV , October 13, 2022, at 9:30 PM PT. New to The Street’s TV show will air the follo...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from A...

The U.S. Food and Drug Administration (FDA) cleared Tonix Pharmaceuticals' ( NASDAQ: TNXP ) application seeking to start a phase 2 of TNX-601 ER to treat major depressive disorder (MDD). TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily formu...

TNX-601 ER, Tianeptine Hemioxalate, is an Extended-Release Tablet for Once-a-Day Dosing Phase 2 Clinical Trial of TNX-601 ER Expected to Start First Quarter 2023 CHATHAM, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) --  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Toni...

NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) -- FMW Media’s New To The Street / Newsmax TV announces its Corporate interviews on the 389th show, airing Sunday, September 25, 2022, 10-11 AM ET: 1). PetVivo Holdings, Inc.’s (NASDAQ: PETV) (NASDAQ: PETVW)...